In researches exploring cellular mechanisms, anti-inflammatory drug screening and immunology-related projects, cellular inflammation models are the most commonly adopted and highly publishable in vitro models. However, most researchers encounter identical troubles: unstable ELISA data, insignificant intergroup differences, poor repeatability, and challenges from journal reviewers questioning model validity.

Many researchers attribute these issues to insufficient sensitivity of ELISA kits or operational errors. In fact, the root causes lie in non-standard inflammation modeling, sloppy experimental protocols, mismatched target selection, and improper sample processing after model construction.

This article exclusively focuses on in vitro cellular inflammation models, thoroughly sorting out mainstream modeling reagents, classic pro-inflammatory/anti-inflammatory targets, standardized modeling workflows, and key troubleshooting tips for experiments.

I. Core Logic of ELISA Assays for Cellular Inflammation Models

The fundamental principle of in vitro cellular inflammation models: exogenous inflammatory inducers stimulate target cells to activate inflammatory pathways, prompting massive secretion of pro-inflammatory cytokines and upregulated expression of inflammation-related proteins. After drug intervention, decreased pro-inflammatory factors and elevated anti-inflammatory factors can be detected to verify the anti-inflammatory mechanism of candidate drugs.

Compared with oxidative stress, apoptosis and metabolism models, inflammation models impose strict requirements on inducer concentration, intervention duration and sample harvesting timing. Minor timing deviation may eliminate peak expression of target proteins, resulting in undetectable differences via ELISA.

II. Mainstream Modeling Reagents for Cellular Inflammation & Compatible Cell Systems

Different inflammatory inducers activate distinct signaling pathways and trigger expression of different targets. Three widely used modeling reagents for ELISA detection are summarized below:

1. LPS (Lipopolysaccharide, the most classic universal inflammatory inducer)

Applicable cells: Macrophages (RAW264.7, THP-1), microglia, tumor cells, vascular endothelial cells, renal tubular epithelial cells, hepatocytes and most somatic cells Mechanism: Binds to TLR4 receptor to activate the canonical NF-κB inflammatory pathway and rapidly trigger acute inflammatory response Common working concentration: 100 ng/mL – 1 μg/mL Optimal modeling duration: 6–24 h (matches peak expression of most inflammatory cytokines)

2. TNF-α (Tumor Necrosis Factor-α, inducer for in vitro inflammatory injury)

Applicable cells: Endothelial cells, fibroblasts, tumor cells, airway epithelial cells Mechanism: Exogenous supplementation of inflammatory cytokines mimics in vivo inflammatory microenvironment and induces secondary cellular inflammation, injury and adhesion Common working concentration: 20–50 ng/mL Optimal modeling duration: 12–24 h

3. IL-1β (Interleukin-1β, inducer for chronic inflammation models)

Applicable cells: Chondrocytes, synoviocytes, neurons, fibrosis-related cells Mechanism: Induces chronic low-grade inflammation, cellular degeneration and concomitant fibrosis Common working concentration: 10–20 ng/mL Optimal modeling duration: 24–48 h

Optimal modeling conditions must be confirmed via preliminary experiments. It is recommended to perform concentration gradient tests within the above concentration range. After determining the proper concentration, collect samples at multiple time points to confirm the optimal incubation length.

III. Core Targets of Inflammation Models: Pro-Inflammatory vs Anti-Inflammatory

Failed experiments mostly stem from ignorance of expression localization and peak time of various targets. Uniform sampling time leads to missed detection of highly expressed targets and non-significant data. We categorized inflammatory targets into pro-inflammatory and anti-inflammatory groups with clarified sample types and detection rationales.

1. Pro-inflammatory Targets (markedly elevated in model group; core detection indicators)

Sample type: Mostly secreted proteins harvested from cell culture supernatant

• IL-6: The gold-standard pro-inflammatory cytokine with the highest sensitivity and largest fluctuation. Its obvious decline after drug intervention makes it the primary indicator for anti-inflammatory mechanistic publications.
• TNF-α: Hallmark cytokine of early acute inflammation with the fastest response. Sharp elevation in early modeling verifies successful model construction.
• IL-1β: Key mediator of chronic inflammation and tissue damage with stable expression, suitable as auxiliary validation marker.
• IL-8: Chemokine reflecting inflammatory cell recruitment, widely applied in endothelial, airway and tumor inflammation models.
• MCP-1 (Monocyte Chemoattractant Protein-1): Classic marker for inflammatory microenvironment and cellular infiltration.

2. Anti-inflammatory Targets

Sample type: Both supernatant-secreted proteins and intracellular proteins

• IL-10: Canonical anti-inflammatory cytokine that negatively regulates inflammatory cascades. Its expression drops significantly in model groups and rebounds in a dose-dependent manner upon effective drug treatment, serving as critical supporting evidence for anti-inflammatory effects.
• TGF-β (Transforming Growth Factor-β): Exerts both anti-inflammatory and tissue reparative functions, commonly used for inflammation injury and combined fibrosis models.
• IL-4, IL-13: Auxiliary anti-inflammatory cytokines, mainly adopted in researches on chronic inflammation and immune balance.

Anti-inflammatory cytokines exhibit more variable expression patterns. In some acute inflammation models, anti-inflammatory factors show slight change or reduction, with possible reactive elevation in later stages. Chronic inflammation models generally sustain low levels of anti-inflammatory cytokines. For successfully intervened models, anti-inflammatory cytokines mostly increase remarkably.

3. Intracellular Inflammatory Pathway Targets

For in-depth mechanistic validation, intracellular pathway proteins including NF-κB p65, p-IκBα, MAPK, JNK and ERK can be tested. These markers require cell lysate preparation rather than supernatant collection.

IV. Standardized Operation Protocol for Cellular Inflammation Modeling

1. Cell seeding: Unify baseline to eliminate systematic errors

Use cells at passages 3–8 in logarithmic growth phase. Prepare single-cell suspension free of cell clumps and dead cells. Adjust seeding density according to target sample type. Gently shake culture plates after seeding and incubate cells at 37 °C with 5% CO₂ for 12–24 h. Initiate modeling only when cells adhere evenly and reach 70%–80% confluence.

2. Grouping and inflammatory intervention

Preliminary experiments define the optimal inducer concentration and sampling time for the inflammation model group. Group setup: Blank control group, inflammation model group, low/medium/high-dose drug intervention groups.

• Blank control: Replenish with fresh complete medium
• Model group: Treated with medium containing LPS/TNF-α/IL-1β at confirmed concentrations
• Drug groups: Pre-treated with test drugs for ~1 h before adding inflammatory inducers

Ensure identical culture conditions, incubation length and environment across all groups. Serum starvation can be conducted to eliminate serum interference for suboptimal experimental results.

V. Common ELISA Troubleshooting for Inflammation Assays

1. No significant differences between blank control and model groups, with unchanged cytokine levels

Causes: Sampling time mismatches target expression peaks; insufficient LPS dosage; lack of serum starvation; cytokine degradation due to prolonged room-temperature storage of samples Solutions: Confirm optimal induction conditions via pre-experiments; standardize serum starvation; collect samples rapidly under low-temperature conditions.

2. High background signals in blank group and irregular data

Causes: Residual serum, leftover modeling reagents, cell debris contamination in samples Solutions: Strict washing and centrifugation to remove impurities; perform modeling in serum-free medium throughout the experiment.

3. Poor repeatability within one batch of experiments

Causes: Inconsistent cell passage numbers, uneven cell density, inconsistent reagent addition timing, large time gaps during sample collection Solutions: Unify cell passage and seeding density in each batch; conduct modeling and sample harvesting synchronously for all wells.

Closing Remarks

Reliable ELISA data for inflammation studies rely on stable model construction and refined sample management. Matching appropriate modeling reagents, corresponding biomarkers and accurate sampling time, paired with high-matching detection kits, generates high-quality data with robust intergroup differences and repeatability for high-impact publications.

As a manufacturer supplying ELISA kits and specific antibodies, we provide full-spectrum human/mouse/rat ELISA kits targeting pro-inflammatory and anti-inflammatory cytokines, as well as site-specific pathway antibodies. Our products feature high specificity, low batch-to-batch variation and sensitivity suitable for detecting low-abundance inflammatory targets, fully supporting cellular inflammation modeling, anti-inflammatory drug mechanism research and academic publishing demands.